Webster Stephen W 4

What Happened Stephen W. Webster, a director of Eloxx Pharmaceuticals, was granted a derivative award covering 13,587 shares on 2026-06-08. The Form 4 reports the acquisition as an award/grant (transaction code A) with an amount of 13,587 and a reported price of $0.00 (no cash exchanged on grant as reported). This is a compensation award, not a market purchase or sale.

Key Details

• Transaction date: 2026-06-08; Form 4 filed: 2026-06-10 (filed promptly).
• Transaction type: Grant/Award of derivative securities (option-like award) — 13,587 shares; reported price $0.00.
• Vesting: Footnote F1 — vests in 24 substantially equal monthly installments; fully vested on the second anniversary of the grant, subject to continuous service.
• Shares owned after transaction: Not disclosed in the provided filing details.
• No indication in this filing of an immediate exercise or sale of underlying shares.

Context

• This is a typical director compensation award rather than a purchase or sale; it represents potential future equity subject to vesting and any exercise requirements. It does not necessarily reflect an immediate cash investment or disposition by the insider.
• Retail investors often view purchases by insiders as a stronger direct signal than routine grants, which are commonly used for retention and compensation.